Cassandra Perkey, PharmD, BCOP

If SG plus pembrolizumab becomes approved in the first-line metastatic TNBC setting, many clinicians anticipate shifting practice patterns to favor this regimen, given its promising efficacy.

From a pharmacologic standpoint, the adverse events associated with sacituzumab govitecan (SG)—particularly neutropenia and diarrhea—are consistent with the mechanism of its payload.

In clinical practice, the approach to G-CSF use with sacituzumab govitecan (SG) is typically individualized based on patient-specific risk factors and prior tolerance.

This section compares the adverse-event patterns of SG plus pembrolizumab versus chemotherapy plus pembrolizumab, emphasizing differences in hematologic and non-hematologic toxicities that inform clinical monitoring.

This segment explains how ASCENT-04 assessed whether moving sacituzumab govitecan into the first-line setting with immunotherapy could improve outcomes for a population with historically limited options.

This segment summarizes the challenges of metastatic TNBC and highlights how current treatment decisions rely on biomarkers and evolving molecular profiling to guide a personalized therapeutic approach.

Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.